Nanomedicine-mediated cancer stem cell therapy

Shen, Song; Xia, Jinxing; Wang, Jun

doi:10.1016/j.biomaterials.2015.09.037

Cited by 118 publications

(84 citation statements)

References 217 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Due to the EPR effect, nanocarriers have recently been used to deliver anti-CSC therapeutics to the tumor site to reduce the population of CSCs. 38,39 However, the drugs delivered by NPs often fail to transport to the CSCs due to the heterogeneity of the tumor and the high drug resistance of CSCs, which would Notes: The 2D-and 3D-cultured 4T1 breast cancer cells were treated with equivalent concentrations of (A) r6g-Peg-Plga, (B) r6g-ha-Peg-Plga, and (C) r6g-DclK1-ha-Peg-Plga NPs for 2 hours at 37°C. The immunofluorescence was visualized using a confocal microscope.…”

Section: Discussionmentioning

confidence: 99%

A novel double-targeted nondrug delivery system for targeting cancer stem cells

Qiao¹,

Zhao²,

Geng³

et al. 2016

IJN

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A novel double-targeted nondrug delivery system for targeting cancer stem cells

Qiao¹,

Zhao²,

Geng³

et al. 2016

IJN

View full text Add to dashboard Cite

“…These formulations use natural or synthetic polymeric materials to encapsulate or absorb drugs, and the carrier materials include polymers, liposomes, micelles, proteins, and metallic materials. Compared with traditional drug delivery systems, nanomedicine has the following advantages: it increases the bioavailability of poorly soluble drugs, prolongs drug circulation time, increases penetrability, permits loading of a variety of drugs, improves drug efficacy and targeting, and reduces toxicity [13,14]. These advantages have contributed to the research interest in nanomedicine-mediated combined chemotherapy and resulted in the successful development of some novel nanomedicine-anticancer drugs.…”

Section: Nanomedicinementioning

confidence: 99%

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Chen¹,

Xie²,

Sun³

et al. 2017

PHARMSCI

View full text Add to dashboard Cite

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy. Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy. Methods:By collecting and referring to the related literature in recent years. Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation time in vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profile in vivo such that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves). Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

show abstract

“…With this phenomenon in mind, an increasing number of CSCtargeted therapeutic agents have been developed over the past several years such as salinomycin, curcumin, thioridazine hydrochloride, sulforaphane, miR-34a, and miR-130b. [94][95][96][97] Despite their therapeutic potential in targeting CSCs, their clinical application has been hindered by their hydrophobicity, poor specificity and poor pharmacokinetics (PK) profiles. [98][99][100] Recent developments in nanoparticle delivery systems have provided new strategies to efficiently deliver therapeutics that can overcome the challenges posed by CSCs and improve therapeutic efficacy of CSC-targeting agents by controlling release kinetics, prolonging circulation time and improving bio-distribution.…”

Section: Nanomedicine In Combination Therapymentioning

confidence: 99%

“…Furthermore, in the study done by Wei and colleagues, salinomycin was conjugated to a hyaluronic acid-based nanogel to target CD44 + drug resistant cells which enhanced the therapeutic efficacy of salinomycin. [97,98] Another advantage of using nanoparticles is the additional capability to modify their surfaces with targeting agents such as mAbs and peptides. High target selectivity and internalization can be achieved by surface modification of nanoparticles with targeting moieties.…”

Section: Nanomedicine In Combination Therapymentioning

confidence: 99%

“…Despite these advances in the laboratory, targeted nanoparticle approaches in the CSC field are still in the early preclinical development stage due to limitations such as potential systemic toxicity, unwanted side effects, and poor extravasation and exposure to their targets. [97,98,102] It has been shown that using a CSC-targeted inhibitor alone is not very effective in reducing the tumor bulk due to the fact that these inhibitors are not highly cytotoxic as compared with conventional chemotherapeutics. Thereby, dual targeting nanoparticles loaded with CSC inhibitors and conventional cytotoxic agents can improve clinical outcomes by effectively eradicating both CSCs and bulk tumor cells at the same time.…”

Section: Nanomedicine In Combination Therapymentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic strategies for targeting cancer stem cells

Kim¹,

Siegler²,

Siriwon³

et al. 2016

JCMT

View full text Add to dashboard Cite

The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer therapy; these shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies. Compelling evidence suggests that cancer stem cells (CSCs) have a crucial impact in current shortcomings of cancer therapy because they are largely responsible for tumor initiation, relapse, metastasis, and chemo-resistance. Thus, a better understanding of the properties and mechanisms underlying CSC resistance to treatments is necessary to improve patient outcomes and survival rates. In this review, the authors characterize and compare different CSC-specific biomarkers that are present in various types of tumors. We further discuss multiple targeting approaches currently in preclinical or clinical testing that show great potential for targeting CSCs. This review discusses numerous strategies to eliminate CSCs by targeting surface biomarkers, regulating CSC-associated oncogenes and signaling pathways, inhibiting drug-efflux pumps involved in drug resistance, modulating the tumor microenvironment and immune system, and applying drug combination therapy using nanomedicine.

show abstract

Nanomedicine-mediated cancer stem cell therapy

Cited by 118 publications

References 217 publications

A novel double-targeted nondrug delivery system for targeting cancer stem cells

A novel double-targeted nondrug delivery system for targeting cancer stem cells

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Therapeutic strategies for targeting cancer stem cells

Contact Info

Product

Resources

About